Exhibit 99.1

The following is a summary of third-quarter 2011 sales by major business category.

(a) Established Pharmaceuticals includes sales of branded generics outside of the United States.

(b) Includes sales primarily from Contract Pharmaceutical Manufacturing and Animal Health.

n/a = Not applicable

2

The following is a summary of nine-month 2011 sales by major business category.

(a) Established Pharmaceuticals includes sales of branded generics outside of the United States.

(b) Includes sales primarily from Contract Pharmaceutical Manufacturing and Animal Health.

n/a = Not applicable

3

The following is a summary of third-quarter 2011 sales for select products.

The following is a summary of nine-month 2011 sales for select products.

n/a = Not applicable

4

Business Highlights

·                 Reported Positive Top-Line Results From Daclizumab Multiple Sclerosis Trial

Announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial designed to evaluate the investigational biologic daclizumab in people with relapsing-remitting multiple sclerosis over one year. The study demonstrated significant reductions in annualized relapse rate and met key secondary endpoints.

·                 Received U.S. Approval for ALK Genetic Test and Launched Test in Europe

Received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC). The new Abbott Vysis ALK Break Apart FISH Probe test is designed to identify ALK-positive NSCLC patients for Pfizer’s approved NSCLC therapy, XALKORI® (crizotinib), an oral first-in-class ALK inhibitor. Abbott also announced the launch of its ALK test in Europe and New Zealand.

·                 Received FDA Approval for Two Three-Month Strengths of Lupron Depot-PED

The FDA approved two new strengths for three-month administration of Lupron Depot-PED® (leuprolide acetate for depot suspension), expanding dosing options for children with central precocious puberty.

·                 Initiated Two Clinical Trials for ABSORB Bioresorbable Vascular Scaffold (BVS)

Announced the initiation of ABSORB BTK, an international clinical trial evaluating the safety and efficacy of the ABSORB™ BVS for the treatment of below-the-knee (BTK) critical limb ischemia, a severe form of peripheral artery disease. Additionally, the first patient in Japan has been treated with Abbott’s ABSORB BVS as part of the ABSORB EXTEND clinical trial, which is now enrolling patients in 20 countries in Europe, Latin America and Asia Pacific.

·                 Announced Expansion of Nutrition Manufacturing Capacity in China

Abbott will build a state-of-the-art nutrition manufacturing facility in Jiaxing, China to meet growing demand. The facility represents Abbott’s largest investment in China to date and will manufacture premium powdered milk products for Chinese infants and children.

·                 Received FDA Approval for RX Herculink Elite Renal Stent System

The FDA approved Abbott’s RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis in patients with uncontrolled hypertension.

·                 Announced Plans for New Formulations of Two HIV Medicines

Announced plans to develop two new formulations of Kaletra® (lopinavir/ritonavir) and Norvir® (ritonavir) for people living with HIV-1. Abbott is currently investigating a new powder formulation of Norvir as well as a co-formulation of three HIV medicines — lopinavir, ritonavir and 3TC (lamivudine).

·                 Received CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery

Expanded the Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of Healon EndoCoat OVD. The product is intended for use as a surgical aid in cataract extraction, intraocular lens (IOL) implantation, corneal transplantation, and glaucoma filtration surgery.

5

Abbott confirms double-digit ongoing earnings-per-share growth for 2011

Abbott is confirming its guidance for double-digit ongoing earnings-per-share growth for the full-year 2011 and is narrowing its previous guidance range. Abbott’s ongoing earnings-per-share guidance for full-year 2011 is $4.64 to $4.66, excluding specified items, reflecting 11.5 percent growth at the midpoint.

Abbott forecasts specified items for the full-year 2011 of approximately $1.54 per share, primarily associated with a $1.5 billion pre-tax reserve related to previously disclosed litigation (see page 7), acquisition integration/cost reduction initiatives, other litigation reserves, and in-process R&D, partially offset by the favorable impact of the resolution of various international and U.S. tax positions. Including these specified items, projected earnings per share under Generally Accepted Accounting Principles (GAAP) would be $3.10 to $3.12 for the full-year 2011.

Abbott declares 351st quarterly dividend

On Sept. 15, 2011, the board of directors of Abbott declared the company’s quarterly common dividend of 48 cents per share. The cash dividend is payable Nov. 15, 2011, to shareholders of record at the close of business on Oct. 14, 2011. This marks the 351st consecutive dividend paid by Abbott since 1924.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott’s news releases and other information are available on the company’s Web site at www.abbott.com. Abbott will webcast its live third-quarter earnings conference call through its Investor Relations Web site at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time.

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2010, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

6

Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings

Third Quarter Ended September 30, 2011 and 2010

(in millions, except per share data)

(unaudited)

1)              2011 Cost of products sold includes approximately $415 million of non-cash intangible amortization.

2)              Research and development expense as reported in both periods was impacted by specified items as noted in Footnote 4. Excluding specified items, ongoing research and development expense increased 8.2 percent.

3)              2011 Selling, general and administrative expense includes $1.5 billion of litigation reserves related to ongoing settlement discussions in the previously disclosed investigation by the U.S. Department of Justice, through the U.S. Attorney for the Western District of Virginia, related to Depakote. The discussions are ongoing, and until concluded, there can be no certainty about definitive resolution.

4)              2011 Net Earnings Excluding Specified Items excludes after-tax charges of $1.4 billion, or $0.92 per share, related to litigation reserves (see Footnote 3 above), $75 million, or $0.05 per share, associated with the acquisition of Solvay Pharmaceuticals and $78 million, or $0.05 per share, for previously announced cost reduction initiatives and other. These items were partially offset by a favorable adjustment to tax expense of $51 million, or $0.03 per share, as a result of the resolution of various prior years’ international and U.S. tax positions.

2010 Net Earnings Excluding Specified Items excludes after-tax charges of $513 million, or $0.33 per share, associated primarily with the acquisition of Solvay Pharmaceuticals, including restructuring plans, as well as cost reduction initiatives, $70 million, or $0.05 per share, for costs of a nutritional product recall and the withdrawal of sibutramine, and $158 million, or $0.10 per share, for impairment of the intangible asset related to sibutramine.

NOTE: See attached questions and answers section for further explanation of Consolidated Statement of Earnings line items.

n/m = Percent change is not meaningful.

7

Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings

Nine Months Ended September 30, 2011 and 2010

(in millions, except per share data)

(unaudited)